Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


katerina.gospodinova@cmd.ox.ac.uk

Katerina Gospodinova

Team Leader- Neuroinflammation

Katerina received her PhD in Genomics and Experimental Medicine from The University of Edinburgh. She joined the University of Oxford in 2021 as a post-doctoral researcher within the TREAT-AD consortium, where she was involved in the design, development and dissemination of molecular and cellular tools for validating novel, next generation therapeutic targets in Alzheimer's disease. She has generated several Target Enabling Packages and developed in vitro assay platforms for high-throughput target validation in hiPSC-derived and immortalized cell lines. 

Katerina joined the Alzheimer's Research UK Oxford Drug Discovery Institute as a Team Leader of the Neuroinflammation group in 2022. Her research focuses on identifying and de-risking neuroimmune and matrisome-associated targets and pathways as potential therapeutic strategies in Alzheimer’s disease and related dementias.